Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc. (NDRA) is an imaging technology company developing the Thermo Acoustic Enhanced UltraSound (TAEUS®) platform, with a primary focus on liver fat quantification for steatotic liver disease (SLD) and metabolic dysfunction‑associated steatohepatitis (MASH). News about ENDRA frequently centers on clinical data, regulatory planning and strategic shifts that affect how its technology may be used in metabolic disease management and drug development.
Recent press releases highlight feasibility and pilot study results in which ENDRA’s thermo‑acoustic fat fraction (TAFF) measurements are compared with MRI‑PDFF, the recognized imaging gold standard for liver fat. These updates provide details on statistical agreement across the SLD spectrum, performance at clinically important liver fat thresholds, and the implications for patient stratification and monitoring in MASLD/MASH and GLP‑1 trials. Investors and clinicians can follow how enhancements to TAEUS Liver’s probe design and algorithms are expected to improve accuracy and repeatability ahead of a planned De Novo pivotal study.
ENDRA news also covers its evolving go‑to‑market strategy, including a pivot toward metabolic disease and GLP‑1 therapy management, identification of key customer segments such as pharmaceutical companies, CROs and metabolic clinics, and plans for a subscription‑based access model. In parallel, the company issues updates on its digital asset treasury (DAT) strategy, including private placements, HYPE token purchases, and staking initiatives managed by Arca Investment Management with custody by Anchorage Digital Bank.
By following NDRA news on this page, readers can track clinical milestones, regulatory interactions, capital markets activity, and developments in ENDRA’s DAT program, all of which shape the company’s trajectory in both medical imaging and digital asset management.
ENDRA Life Sciences (NASDAQ: NDRA) announced financial results for Q1 2022, reporting a net loss of $2.9 million, or $0.07 per share, compared to a net loss of $2.3 million, or $0.06 per share, in Q1 2021. The company raised $8.7 million in gross proceeds, extending its cash runway. ENDRA clarified its U.S. regulatory strategy for its TAEUS Liver System, targeting a De Novo submission in Q3 2022. Additionally, it expanded into China with a new clinical partner, grew its IP portfolio to 90 assets, and received ISO 13485:2016 recertification, enhancing its operational credibility.
ENDRA Life Sciences (NASDAQ: NDRA) has announced the issuance of four new patents, augmenting its global patent portfolio to 90 assets, including 46 issued patents. Two patents were issued in the U.S. and two in China, further protecting the TAEUS® system, which utilizes hybrid ultrasound and thermoacoustic imaging technology. Notably, one U.S. patent allows data transfer without an internet connection, paving the way for potential licensing opportunities in data management. This innovation not only strengthens ENDRA’s proprietary position but also presents new revenue generation avenues.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report its Q1 2022 financial results on May 12, 2022, post-market close. The management team will host a conference call at 4:30 PM ET to discuss the results and recent developments. Pre-registration for the call is encouraged via a provided link. A replay will be available until May 19, 2022, along with an accessible webcast for those unable to attend. ENDRA is known for its innovative TAEUS® technology, aimed at improving the diagnosis of liver diseases and other clinical applications.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) raised
ENDRA Life Sciences (NASDAQ: NDRA) has received ISO 13485:2016 recertification from the British Standards Institution. This certification indicates the company's adherence to quality management standards essential for the medical device sector. It confirms the robust foundation of ENDRA's Quality Management System, which is critical for its TAEUS® technology. The recertification further supports ENDRA's strategy in developing thermoacoustic imaging systems to address unmet clinical needs, particularly in liver health diagnostics and energy-based surgical procedures.
ENDRA Life Sciences (NASDAQ: NDRA) reported its fourth quarter and full year 2021 results, highlighting a net loss of $3.1 million, or $0.07 per share, for Q4, compared to a net loss of $2.3 million in Q4 2020. Full-year net loss stood at $11.2 million, or $0.28 per share, an improvement from $11.7 million in 2020. The company achieved clarity on its U.S. regulatory strategy for its TAEUS system, pursuing a De Novo pathway, and expanded its clinical partnerships in China and Europe. Cash and equivalents as of December 31, 2021, were $9.5 million, supporting ongoing commercial activities.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has received two new patents from the Chinese National Intellectual Property Administration, enhancing its intellectual property in the Chinese market. The patents, titled ‘927 and ‘250, focus on methods for determining tissue fat content and a radio frequency applicator for the TAEUS technology. With 11 patents now in China and a total of 89 globally, ENDRA aims to improve diagnostic tools for liver conditions affecting over one billion people. This development comes shortly after the announcement of a research partnership with Shanghai General Hospital.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will release its fourth quarter 2021 financial results on March 30, 2022, after U.S. markets close. A conference call and webcast will follow at 4:30 p.m. Eastern time, covering the results and recent corporate developments. Interested participants are encouraged to pre-register for the call or can join via specific dial-in numbers. The company is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology aimed at liver health assessments, which could revolutionize diagnostic practices for chronic liver diseases.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced participation in two investor conferences in March. The company will attend the 34th Annual ROTH Conference from March 13-15, 2022, where management will be available for one-on-one meetings on March 14 and a pre-recorded presentation will be posted online. Additionally, ENDRA will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 15 at 2:40 p.m. ET and offer virtual one-on-one meetings. ENDRA is known for its TAEUS® technology for liver health assessment.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted U.S. Patent No. 11266314, which protects its TAEUS technology's method for determining material types. This patent enhances ENDRA's intellectual property strategy, potentially expanding applications beyond liver measurements and into broader clinical and non-clinical spheres. Currently, the company holds 89 intellectual property assets globally. ENDRA aims to revolutionize diagnostic imaging at lower costs, particularly addressing chronic liver conditions affecting over one billion people.